Westfield Capital Management
SAGE icon

Westfield Capital Management’s Sage Therapeutics SAGE Stock Holding History

Westfield Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-353,603
Closed -$30.6M – 277
2020
Q4 		$30.6M Sell
353,603
-201,870
-36% -$14.9M 0.18% 156
2020
Q3 		$34M Sell
555,473
-6,984
-1% -$354K 0.22% 134
2020
Q2 		$23.4M Buy
562,457
+135,765
+32% +$4.93M 0.16% 158
2020
Q1 		$12.3M Buy
426,692
+179,483
+73% +$10.4M 0.11% 170
2019
Q4 		$17.8M Buy
247,209
+100,248
+68% +$12.3M 0.13% 172
2019
Q3 		$20.6M Buy
+146,961
New +$24.6M 0.17% 155

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Westfield Capital Management's SAGE Position: Q1 2021 in Review

Westfield Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2021, closing a stake of 353,603 shares — an estimated $30.6M sold.

Westfield Capital Management first reported a position in SAGE in Q3 2019 and held it in 6 quarters. The position peaked at $34M in Q3 2020. 263 funds tracked by Wall St. Rank hold SAGE as of Q1 2021.

  • Westfield Capital Management reported no remaining Sage Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Westfield Capital Management sold 353,603 Sage Therapeutics shares in Q1 2021, an estimated $30.6M.
  • Westfield Capital Management first reported a position in Sage Therapeutics in Q3 2019 and held it in 6 quarters.
  • Westfield Capital Management's Sage Therapeutics position peaked at $34M in Q3 2020.
  • 263 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2021.

Based on Westfield Capital Management's 13F filing for Q1 2021, filed 14 May 2021.